Pharmacy PSE in U.K. works
This article was originally published in The Tan Sheet
Executive Summary
A U.K. advisory panel determines behind-the-counter sales of nonprescription products containing epehedrine or pseudoephedrine effectively mitigate misuse of the drugs. The Medicines and Healthcare products Regulatory Agency's Commission on Human Medicines concluded in July that regulatory measures are "successful" and recommends maintenance of existing pharmacist monitoring and education programs. The report follows MHRA's July 2009 decision to not make precursors of methamphetamine prescription-only (1"The Tan Sheet" Aug. 3, 2009, In Brief)
You may also be interested in...
U.K. to keep PSE meds BTC
Restrictions on sales of drugs containing ephedrine and pseudoephedrine in the U.K. have proven effective in decreasing illicit methylamphetamine production, so the Medicines and Healthcare products Regulatory Agency will not shift the products to prescription only status. In August 2007, an agency advisory panel recommended ephedrine and PSE products be sold in packages no larger than 720 mg and its Commission on Human Medicines recommended limiting sales of the drugs to pharmacy only and to one package per person (1"The Tan Sheet" Jan. 14, 2008). MHRA said July 29 in wake of the changes, meth abuse has been contained and pharmacies have seen a 25 percent drop in PSE purchases. An executive said the agency will continue to monitor sales of the meth precursors
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.